CervoMed (CRVO) to Release Quarterly Earnings on Monday

CervoMed (NASDAQ:CRVO) is projected to post its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($0.79) per share and revenue of $0.8430 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 9:30 AM ET.

CervoMed Price Performance

NASDAQ CRVO opened at $4.11 on Monday. The stock has a market capitalization of $38.03 million, a price-to-earnings ratio of -1.42 and a beta of -0.77. CervoMed has a one year low of $1.92 and a one year high of $16.94. The business’s fifty day moving average is $5.83 and its 200-day moving average is $7.47.

Institutional Investors Weigh In On CervoMed

Institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC bought a new position in CervoMed during the first quarter worth about $227,000. Rhumbline Advisers raised its position in shares of CervoMed by 35.5% in the first quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock valued at $53,000 after purchasing an additional 1,526 shares during the period. Marshall Wace LLP bought a new stake in shares of CervoMed in the second quarter valued at approximately $76,000. Jane Street Group LLC purchased a new stake in shares of CervoMed during the 2nd quarter valued at approximately $414,000. Finally, Vanguard Group Inc. boosted its holdings in CervoMed by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 343,463 shares of the company’s stock worth $2,779,000 after buying an additional 3,445 shares during the period. 25.15% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on CRVO. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of CervoMed in a report on Thursday, December 18th. Brookline Capital Acquisition upgraded shares of CervoMed to a “strong-buy” rating in a research note on Tuesday, February 3rd. Zacks Research raised shares of CervoMed from a “strong sell” rating to a “hold” rating in a research report on Monday, January 12th. Chardan Capital restated a “buy” rating and set a $15.00 price target on shares of CervoMed in a research note on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CervoMed in a report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, CervoMed has a consensus rating of “Moderate Buy” and an average target price of $22.17.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.